9/12 5:30 pm - 8:30 pm
HBA presents 'Putting Academia-Industry Research Partnerships to Work.' Novartis, 1 Health Plaza, East Hanover, NJ more
9/24 4:00 pm - 6:00 pm
CURE presents healthcare investment banker Anthony Gibney of Leerink Swann. Yale Anlyan Center, 300 Cedar Street, New Haven more
10/1 4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Trevi Therapeutics. Anlyan Center, 300 Cedar Street, New Haven. Watch for details.
10/8-9 12th annual BIO Investor Forum. The Palace Hotel, San Francisco more
10/15 6:00 pm - 9:30 pm
HBA presents Women's Healthcare Innovation and Leadership Showcase. Sanofi Campus, 55 Corporate Drive Auditorium, Bridgewater, NJ more
11/7 10:00 am - 3:00 pm
CT Innovation Summit. Mentor meetings, awards ceremony, and more. Co-sponsored by CURE. Oakdale Theater, Wallingford more
11/11-13 The BIO Convention in China. National Convention Center, Beijing more
12/3 5:45 pm - 7:30 pm
CURE Holiday Party. 'The best networking in town.' Café George, 300 George Street, New Haven. Save the Date!

Cost-saving discounts for CURE members!
CURE members can now receive discounts on various products and services, such as lab supplies, shipping services, and gases more

MannKind Corporation
One Casper Street
Danbury, CT 06810

Phone: 203-790-3121
Website: http://www.mannkindcorp.com

Daniel J. Giannini, Director, Human Resources - dgiannini@mannkindcorp.com

General Information

MannKind Corporation is a world-class biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products to treat diseases such as diabetes and cancer across the globe. Under the leadership of our Chairman and CEO, Al Mann, who has devoted his life to filling unmet medical needs, we use our proprietary technologies and breakthrough discoveries, striving to cure diseases and improve disease management.

Our lead investigational product candidate, the Technosphere® Insulin System, is currently in Phase 3 clinical trials to study its safety and efficacy in the treatment of diabetes. This dry powder therapy consists of our proprietary Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using our proprietary MedTone inhaler. We believe that the performance characteristics, unique kinetics, convenience and ease of use of the Technosphere® Insulin System may have the potential to change the way diabetes is treated.

In order to deliver results, meet commitments and strive to be the best, our employees apply MannKind values in all aspects of work.

• Teamwork • Accountability • Quality• Communication • Integrity• Enthusiasm• Trust and Respect • Execution

As we work to improve the lives of people worldwide, we invite you to learn more about MannKind Corporation.